Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18609
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFirkin, Frank-
dc.contributor.authorRoncolato, Fernando-
dc.contributor.authorHo, Wai Khoon-
dc.date2015-03-23-
dc.date.accessioned2018-08-30T06:23:41Z-
dc.date.available2018-08-30T06:23:41Z-
dc.date.issued2015-10-
dc.identifier.citationEuropean journal of haematology 2015; 95(4): 331-5-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18609-
dc.description.abstractTo determine the potential for arsenic trioxide (ATO) to be safely and effectively incorporated into induction therapy of newly diagnosed acute promyelocytic leukaemia (APL) in patients with severe chronic renal failure (CRF) by reduction of the ATO dosage to compensate for reduced renal elimination of arsenic in CRF. Two of the four CRF patients with APL in the study were dialysis-dependent, and two had eGFRs of 18 and 19 mL/min/1.73 m(2) . ATO dosage schedules were adjusted to obtain comparable whole-blood arsenic levels to those in APL patients with normal renal function who achieved molecular remission (MR) while receiving 10 mg ATO daily for 28 d. Average ATO administered per day in CRF patients ranged from 36 to 50% of the ATO administered to APL patients with normal renal function. No clinically significant cardiac, hepatic or other toxicities were detected. RT-PCR-negative MR was achieved after one treatment course in two patients and after two courses in the others. Relapse-free survival is 155, 60, 43 and 5 months. The observations in this pilot study have demonstrated whole-blood arsenic levels can provide a guide to adjustments of ATO dosage schedules that permit safe and effective therapeutic outcomes in APL patients with severely compromised renal function.-
dc.language.isoeng-
dc.subjectacute promyelocytic leukaemia-
dc.subjectarsenic blood level monitoring-
dc.subjectarsenic trioxide-
dc.subjectchronic renal failure-
dc.subjectdosage adjustment-
dc.titleDose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.-
dc.typeJournal Article-
dc.identifier.journaltitleEuropean journal of haematology-
dc.identifier.affiliationDepartment of Medicine, St Vincent's Hospital, Melbourne University, Fitzroy, Victoria, Australia-
dc.identifier.affiliationDepartment of Haematology, St George Hospital, Kogarah, NSW, Australia-
dc.identifier.affiliationDepartment of Haematology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1111/ejh.12502-
dc.identifier.pubmedid25600167-
dc.type.austinJournal Article-
local.name.researcherHo, Wai Khoon
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptPathology-
crisitem.author.deptLaboratory Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Jul 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.